US FDA approves Gilead's twice-yearly injection for HIV prevention

FDA Approves First Twice-a-Year HIV Prevention Shot

Key Takeaways

Injection Claimed To Prevent HIV Approved By FDA

The Food and Drug Administration (FDA) approved a twice-yearly injection developed to prevent HIV. The first and only of its kind drug, manufactured by Gilead Sciences, will be sold under the name Yeztugo (lenacapavir). WATCH: #GileadNews: The FDA has approved our injectable HIV-1 prevention medication, making it the first and only twice-yearly #HIV prevention option...

FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag - Gilead Sciences (NASDAQ:GILD)

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over its $28K annual price.

The FDA Just Approved a Long-Lasting Injection to Prevent HIV

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming infected with HIV. But big questions remain over the drug’s affordability.

US FDA approves HIV prevention drug: Why is this a breakthrough?

Phase 3 trials show 99.9% of people remained HIV negative with two annual shots

Health activists pressure Gilead to drop price of anti-HIV jab

Accelerating global access to affordable injectable lenacapavir should be top priority, says HJI director Fatima Hassan